Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sabin oral poliovirus vaccine type 2
- Development stage
- Phase 2
- Lead developer
- University of Antwerp
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Sabin oral poliovirus vaccine type 2 (mOPV2) is a live attenuated oral vaccine historically used for the prevention and outbreak control of poliomyelitis caused by type 2 poliovirus. It contains live attenuated poliovirus type 2 derived from the Sabin strain (P712, Ch, 2ab). Administered orally, the vaccine replicates in the intestinal mucosa, inducing robust systemic humoral and local mucosal immune responses. Following the global cessation of trivalent oral poliovirus vaccine (tOPV) in 2016, mOPV2 has been maintained in stockpiles for emergency outbreak response to circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks, though it is increasingly being replaced by the genetically stabilized novel oral poliovirus vaccine type 2 (nOPV2) to reduce the risk of reversion to neurovirulence.
- Brand names
- Polio Sabin Mono Two
- Other names
- mOPV2mOPV-2mOPV 2Sabin monovalent OPV2monovalent oral poliovirus vaccine type 2Sabin monovalent oral poliovirus vaccine type 2Polio Sabin Mono Two (oral)
Beyond the preview
Go deeper on sabin oral poliovirus vaccine type 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sabin oral poliovirus vaccine type 2.